The Safety and Efficacy of Administrating DiaPep277® Vaccination in Type 1 Diabetes Patients.

Trial Profile

The Safety and Efficacy of Administrating DiaPep277® Vaccination in Type 1 Diabetes Patients.

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Peptide p277 (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Mar 2017 Planned primary completion date changed from 1 Aug 2014 to 1 Jan 2016.
    • 19 Mar 2017 Planned initiation date changed from 1 Aug 2013 to 1 Jan 2015.
    • 19 Mar 2017 Status changed from not yet recruiting to withdrawn prior to enrolment because the manufacturer decided to halt manufacturing the vaccine .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top